# Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients

> **NCT04079413** · PHASE3 · COMPLETED · sponsor: **Geropharm** · enrollment: 264 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** GP40071
- **DRUG:** NovoRapid® Penfill®

## Key facts

- **NCT ID:** NCT04079413
- **Lead sponsor:** Geropharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2020-01-21
- **Final completion:** 2020-01-21
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04079413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04079413, "Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04079413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*